Results 11 to 20 of about 76,984 (297)
Background. Tacrolimus has unpredictable pharmacokinetic (PK) characteristics, which are partially attributed to CYP3A5 polymorphism. The potential effects of clinical factors in the postoperative period of transplantation on tacrolimus PK and those of ...
Fang Cheng+5 more
doaj +1 more source
Background: Switching to cyclosporin A may result in a reversion of tacrolimus-induced diabetes mellitus. However, mechanisms underlying such a reversion are still unknown.
Ana Elena Rodríguez-Rodríguez+9 more
doaj +1 more source
Background : Once-daily tacrolimus reduces non-compliance relative to twice-daily tacrolimus. However, little is known about the safety and efficacy of conversion from twice-daily tacrolimus to generic once-daily tacrolimus in liver transplantation (LT).
Jong Man Kim+17 more
doaj +1 more source
Antecedentes: El cambio a ciclosporina A podría revertir la diabetes inducida por tacrolimus. Sin embargo, los mecanismos de esta reversibilidad se desconocen. Métodos: Usamos como modelo de diabetes inducida por tacrolimus las ratas Zucker obesas.
Ana Elena Rodríguez-Rodríguez+9 more
doaj +1 more source
Background Tacrolimus is a key drug in immunosuppressive therapy following lung transplantation. The blood tacrolimus levels are likely to fluctuate in the early postoperative period, and failure to maintain the tacrolimus trough level in target ranges ...
Yoshiki Katada+12 more
doaj +1 more source
Tacrolimus in Renal Transplantation [PDF]
Tacrolimus (Prograf-FK506) has been used since 1989 as a primary immunosuppressive agent in adult and pediatric renal transplant recipients at our institution.1,2 This report will summarize our experience with it over the past six years and will demonstrate its overall efficacy and superiority.
Shapiro, R+15 more
openaire +3 more sources
Tacrolimus is an essential immunosuppressant for the prevention of rejection in solid organ transplantation. Its low therapeutic index and high pharmacokinetic variability necessitates therapeutic drug monitoring (TDM) to individualise dose.
Benedetta C. Sallustio+1 more
doaj +1 more source
Tacrolimus in membranous nephropathy [PDF]
To the Editor: In a recent issue of the Journal, Praga et al.1 reported their experience with tacrolimus monotherapy in patients with idiopathic membranous nephropathy. The authors concluded that tacrolimus was a very useful therapeutic option. This conclusion was based on the findings of a higher remission rate and a reduced risk of deterioration of ...
openaire +3 more sources
The present study aimed to explore the population pharmacokinetics and initial dose optimization of tacrolimus in children with severe combined immunodeficiency (SCID) undergoing hematopoietic stem cell transplantation (HSCT).
Xiao Chen+5 more
doaj +1 more source
In this study of the gut mucosal microbiota in primary sclerosing cholangitis (PSC), we found consistent microbiota features associated with PSC and recurrent PSC, PSC with inflammatory bowel disease and a persistent gut dysbiosis after liver transplantation Abstract Background and Aims Several characteristic features of the fecal microbiota have been ...
Mikal Jacob Hole+12 more
wiley +1 more source